Share issue
January 2019
Oncopeptides has completed a directed share issue of approximately SEK 546 million
January 24, 2019 – Regulatory press release
Oncopeptides AB announces that the Company has successfully completed a directed share issue of approximately SEK 546 million.
The board of directors of Oncopeptides has, based on the issue authorization granted by the annual general meeting on 17 May 2018, and as indicated in the Company’s press release on 23 January 2019, resolved on a directed share issue of 4,750,000 new shares (the “New Shares”) at a subscription price of SEK 115 per share (the “Issue”), which means that the Company will receive gross proceeds of approximately SEK 546 million.
Oncopeptides intends to carry out a directed share issue
January 23, 2019 – Regulatory press release
Oncopeptides AB announces its intention to execute a directed share issue to Swedish and international institutional investors (the “Issue”). The Company has retained Jefferies International Limited, Carnegie Investment Bank AB (publ) and DNB Markets, a part of DNB Bank ASA, to act as Joint Bookrunners (the “Joint Bookrunners”) in connection with the Issue.
The subscription price and the total number of new shares in the Issue (the “Issue Shares”) will be determined through an accelerated bookbuild procedure (the “Bookbuilding”). It is intended that the number of newly issued shares will amount to approximately 10 percent of the total number of shares in the Company. The Bookbuilding will start immediately following this announcement.